RxDoctor Payments DataLook up a doctor →

Kimberly Canaday

Acute Care · Florence, ALNPI 1548280845

Payments from drug & device makers

$13,099in general payments, 2019–2025

Across 637 payments — averaging $20.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novartis$2K
  • Merck$571
  • Seagen Inc.$475
  • Pfizer$450
  • Incyte Corporation$443
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$12,82598%
  • Education$2752%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)62$1,871
Novartis108$1,725
Merck28$571
Seagen Inc.17$475
Pfizer28$450
Incyte Corporation19$443
Amgen25$442
Exelixis Inc.20$437
Johnson & Johnson20$404
Bristol Myers Squibb18$359
Boehringer Ingelheim12$296
Pharmacyclics LLC, An Abbvie Company17$277
Gilead(2 entities)17$275
Lilly USA, LLC19$274
Eisai Inc.14$266
Array Biopharma Inc13$259
AbbVie13$257
E.r. Squibb & Sons, L.L.C.16$254
Sanofi11$234
GSK13$232
Stemline Therapeutics Inc.5$217
Takeda Pharmaceuticals U.S.A., Inc.9$201
Bayer10$196
Astellas Pharma US Inc8$187
Beone Medicines USA, Inc.9$168
Tersera Therapeutics LLC7$160
Sobi, Inc5$158
Genentech USA, Inc.8$151
Jazz Pharmaceuticals Inc.7$149
Beigene USA, Inc.8$147
Janssen Scientific Affairs, LLC1$144
Daiichi Sankyo Inc.7$138
AVEO Pharmaceuticals, Inc.8$122
Pharmacosmos Therapeutics Inc.3$116
Blueprint Medicines Corporation5$115
Puma Biotechnology, Inc.2$98
Regeneron Healthcare Solutions, Inc.5$84
Coherus Oncology, Inc.4$82
Karyopharm Therapeutics Inc.4$69
Dendreon Pharmaceuticals LLC2$63
Pharmaessentia USA Corporation2$47
Kyowa Kirin, Inc.2$41
Geron Corporation2$41
EMD Serono, Inc.2$37
Genmab U.S., Inc.2$36
Sumitomo Pharma America, Inc.2$28
Iovance Biotherapeutics, Inc.2$23
Springworks Therapeutics, Inc.1$21
Shield Therapeutics Inc1$20
Tolmar, Inc.1$20
Acceleron Pharma, Inc.1$20
Deciphera Pharmaceuticals Inc.1$19
Servier Pharmaceuticals LLC1$18
G1 Therapeutics, Inc.1$18
Myovant Sciences Inc.1$18
Adaptive Biotechnologies Corporation1$17
ADC Therapeutics America, Inc.1$16
Recordati_rare_diseases_inc.1$16
Rigel Pharmaceuticals, Inc.1$16
Agios Pharmaceuticals, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,099 in reported general payments places this provider in the 95th percentile of 711 acute care providers in Alabama.

See all acute care providers in Alabama

Medicare billing

Part B allowed, 2024
$23,727
Medicare patients
195
Services billed
296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban22$14,707
Letrozole63$1,440
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen36$1,038
Exemestane13$786
Potassium Chloride74$733
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen31$696
Ondansetron OdtOndansetron32$405
Ondansetron Hcl33$376
Hydroxyurea15$373
Tramadol Hcl17$364
Gabapentin23$300
Mirtazapine42$268
Dexamethasone24$258
Duloxetine Hcl12$252
Anastrozole31$241

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$450$14,70722 claims
Lilly USA, LLCOlanzapine$274$13613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 711 acute care providers in Alabama.

Other acute care in Florence

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →